News Column

Pdl Biopharma, Inc. Files SEC Form 8-K, Current Report (May. 30, 2014)

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Pdl Biopharma, Inc. (Form 8-K) was posted on May 30, 2014.

The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).

There was one document filed with this form. The SEC file number is 0001437749-14-010293.

The contact information for this company is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451, 775-832-8500.

Our editors provided additional information about Form 8-K: This is the "current report" that is used to report the occurrence of any material events or corporate changes which are of importance to investors or security holders and previously have not been reported by the registrant. It provides more current information on certain specified events than would Forms 10-Q or 10-K.

A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

For additional information on this SEC filing see:

Keywords for this news article include: Pharmaceutical Companies, Drugs, Therapy, SEC Filing, Biopharmaceuticals, Pdl Biopharma Inc., Biological Products, (No Diagnostic Substances).

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters